prednisone,niraparib,abiraterone
janssen
['brca', 'magnitude study']
an honor to present this important 2nd interim analysis of magnitude study . continued consistent benefit in brca subgroup with meaningful rpfs benefit and all secondary endpoints in support #ascogu23 all 3 trials reproduce this report ! brca subgroup needs parpi +arpi 
Genitourinary Oncology Section Chief Houston Methodist Cancer Center